Evaluation of PTGS2 Expression, PIK3CA Mutation, Aspirin Use and Colon Cancer Survival in a Population-Based Cohort Study

[1]  Neil Skolnik,et al.  Predictive Value , 2020, Annals of Internal Medicine.

[2]  B. Møller,et al.  Aspirin As Secondary Prevention in Patients With Colorectal Cancer: An Unselected Population-Based Study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  J. Cuzick,et al.  PIK3CA Mutation, Aspirin Use after Diagnosis and Survival of Colorectal Cancer. A Systematic Review and Meta-analysis of Epidemiological Studies. , 2016, Clinical oncology (Royal College of Radiologists (Great Britain)).

[4]  P. Elwood,et al.  Aspirin in the Treatment of Cancer: Reductions in Metastatic Spread and in Mortality: A Systematic Review and Meta-Analyses of Published Studies , 2016, PloS one.

[5]  M. V. van Oijen,et al.  Timing of adjuvant chemotherapy and its relation to survival among patients with stage III colon cancer. , 2015, European journal of cancer.

[6]  T. Yeatman,et al.  Impact of regular aspirin use on overall and cancer-specific survival in patients with colorectal cancer harboring a PIK3CA mutation , 2015, Acta oncologica.

[7]  Stephen McQuaid,et al.  The prognostic significance of the aberrant extremes of p53 immunophenotypes in breast cancer , 2014, Histopathology.

[8]  J. Meyerhardt,et al.  Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology , 2014, Oncogene.

[9]  P. Kuppen,et al.  Expression of HLA class I antigen, aspirin use, and survival after a diagnosis of colon cancer. , 2014, JAMA internal medicine.

[10]  D. Powe,et al.  Low-dose aspirin use after diagnosis of colorectal cancer does not increase survival: a case-control analysis of a population-based cohort. , 2014, Gastroenterology.

[11]  D. Kerr,et al.  Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Carsten Denkert,et al.  Cutoff Finder: A Comprehensive and Straightforward Web Application Enabling Rapid Biomarker Cutoff Optimization , 2012, PloS one.

[13]  Reiko Nishihara,et al.  Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. , 2012, The New England journal of medicine.

[14]  Greg Yothers,et al.  Mutation Profiling and Microsatellite Instability in Stage II and III Colon Cancer: An Assessment of Their Prognostic and Oxaliplatin Predictive Value , 2012, Clinical Cancer Research.

[15]  L. Hou,et al.  Recreational physical activity, body mass index, and survival in women with colorectal cancer , 2012, Cancer Causes & Control.

[16]  P. Rothwell,et al.  Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. , 2012, The Lancet. Oncology.

[17]  P. Rothwell,et al.  Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials , 2012, The Lancet.

[18]  Oliver Nussbaumer,et al.  Novel Aspects of Mevalonate Pathway Inhibitors as Antitumor Agents , 2012, Clinical Cancer Research.

[19]  W. Mackillop,et al.  Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: a systematic review and meta-analysis. , 2011, JAMA.

[20]  S. Chambers,et al.  The Impact of Body Mass Index and Physical Activity on Mortality among Patients with Colorectal Cancer in Queensland, Australia , 2011, Cancer Epidemiology, Biomarkers & Prevention.

[21]  E. Giovannucci,et al.  Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field , 2010, Gut.

[22]  J. Kaur,et al.  PI3-kinase/Wnt association mediates COX-2/PGE2 pathway to inhibit apoptosis in early stages of colon carcinogenesis: chemoprevention by diclofenac , 2010, Tumor Biology.

[23]  S. Paik,et al.  A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes , 2010, BMC Cancer.

[24]  Samy Suissa,et al.  Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes , 2010, BMJ : British Medical Journal.

[25]  K. Al-Kuraya,et al.  Cyclooxygenase‐2 inhibition inhibits PI3K/AKT kinase activity in epithelial ovarian cancer , 2010, International journal of cancer.

[26]  R. Perera,et al.  Adaptation and validation of the Charlson Index for Read/OXMIS coded databases , 2010, BMC family practice.

[27]  S. Ogino,et al.  Aspirin Use and Survival After Diagnosis of Colorectal Cancer , 2009 .

[28]  P. Elwood,et al.  Aspirin, salicylates, and cancer , 2009, The Lancet.

[29]  L. Cantley,et al.  PI3K pathway alterations in cancer: variations on a theme , 2008, Oncogene.

[30]  J. Lewis,et al.  Chronic statin therapy and the risk of colorectal cancer , 2008, Pharmacoepidemiology and drug safety.

[31]  D. English,et al.  Effect of physical activity and body size on survival after diagnosis with colorectal cancer , 2005, Gut.

[32]  P. Croft,et al.  Factors affecting over-the-counter use of aspirin in the secondary prophylaxis of cardiovascular disease. , 2001, The British journal of general practice : the journal of the Royal College of General Practitioners.

[33]  E B Cox,et al.  Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors. , 1986, Cancer research.

[34]  D. Kerr,et al.  Evaluation of PIK 3 CA Mutation As a Predictor of Benefit From Nonsteroidal Anti-Inflammatory Drug Therapy in Colorectal Cancer , 2018 .

[35]  V. Poylin.  Effect of daily aspirin on risk of cancer metastasis: A study of incident cancers during randomised controlled trials , 2013 .

[36]  M. Salto‐Tellez,et al.  Reliability of Tissue Microarrays in Detecting Protein Expression and Gene Amplification in Breast Cancer , 2003, Modern Pathology.